Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in children with active juvenile psoriatic arthritis
NL-OMON60063Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile psoriatic arthritis (JPsA) comparing Apremilast with Placebo (2 arms). Primary endpoint: ACR Pedi 30 response. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
apremilast
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NL-OMON60063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60063.